最新发布
Late Rains, Tight Windows Challenge Weed Control In Kansas Row Crops
July 2026, Manhattan: Heavy rains and fast-growing crops are tightening the window for effective herbicide applications …
Report card from California: Farmers and investors need more education on ag biologicals
The ag biologicals sector is still making “steady progress” in terms of new products and overall growth, Dr.…
WuXi AppTec bets on expansion in Europe
WuXi AppTec, the Chinese life sciences services company, is one of the world’s largest providers of research, development, and manufacturing services (CRDMO) for the pharmaceutical and biotechnology industries. The company supports customers across the entire value chain – from early drug discovery through preclinical and clinical development to commercial manufacturing. A science-driven organization, WuXi AppTec has built an international footprint through strategic acquisitions. Its protein design center in Gräfelfing, near Munich, is now being developed into the company’s European center of excellence for drug discovery. We spoke with Steve Yang, PhD, Co-CEO of WuXi AppTec.
GRDC Farm Business Updates come to Pittsworth, Goondiwindi and Narrabri this July
July 2026, AU: Grain growers and advisers across southern Queensland and northern New South Wales will have the opportun…
🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…
🎥 Can non thermal plasma seed treatment move from lab curiosity to broadacre reality?
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …
🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…
🎥 Can non thermal plasma seed treatment move from lab curiosity to broadacre reality?
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …
Novel Epigenetic Therapy Targets Treatment-Resistant and TP53-Mutant AML
Credit: Andresr/Getty Images The results of a preclinical study by researchers at the University of Texas MD Anderson Cancer Center have found that an investigational epigenetic therapy called NTX-301 remained effective in treatment-resistant acute myeloid leukemia (AML) by activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance.
Guest article: The wizard, the prophet, and the case for regenerative agriculture
Robert Appleby is founder and chief investment officer at Cibus Capital, a London-based private equity platform investin…
